Outcomes in patients with advanced gastrointestinal stromal tumor who did not have baseline ctDNA in the INTRIGUE study

Jonathan Trent1, Robin L Jones2, Suzanne George3, Hans Gelderblom4, Margaret von Mehren5, John R Zalcberg6, Yoong-Koo Kang7, Albruni Abdul Razak5, Steven Attia5, Axel Le Cesne8, William Reichmann9, Kam Sprott10, Haroun Achiou8, Matthew L Sherman11, Rodrigo Ruz-Soto11, Jean-Yves Blay12, Michael C Heinrich13,14, Sebastian Bauer14,15 on behalf of the INTRIGUE investigators

1. Abstract: 11536

2. Introduction

3. Results

4. Safety

5. Methods

6. Table 1. Patient demographics and baseline clinical characteristics

7. Figure 1. INTRIGUE study design

8. Figure 2. ctDNA analysis and detection

9. Figure 3. Kaplan-Meier analysis of PFS (A) or OS (B) with ctDNA-D vs ctDNA-N (Table 2).

10. Figure 4. Kaplan-Meier analysis of PFS for patients treated with ripretinib or sunitinib in both the ctDNA-D and ctDNA-N groups (Figure 4).

11. Figure 5. Forest plot of PFS by RIT mutational status as determined by local pathology report at randomization.

12. Table 2. ORR in patients with ctDNA-D vs ctDNA-N (Table 2).

13. Table 3. TEAE summary for patients with ctDNA-D and ctDNA-N

14. CONCLUSIONS

15. References